Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

11 clinical studies listed.

Filters:

Radiation

Tundra lists 11 Radiation clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07398209

GCC 2546- Motion Management

The purpose of this study is to assess a real time motion tracking of lung tumors and important organs next to the tumor while breathing during a participant's radiation treatment. This will be assessed through a four-dimensional magnetic resonance imaging (MRI) scan before starting your radiation treatment and x-ray fluoroscopy images that are taken during radiation

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-09

1 state

Lung Cancer (NSCLC)
Radiation
RECRUITING

NCT06295783

Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect

To learn more about how you would rate the intensity or severity of your symptoms during or after radiation therapy using questionnaires with different rating scales.

Gender: All

Ages: 18 Years - Any

Updated: 2026-01-14

1 state

Radiation
RECRUITING

NCT04069884

RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer

The purpose of this study is to validate whether clinically low-risk, and RecurIndex high-risk N1 patients receiving regional lymph node radiotherapy can further improve clinical outcomes.

Gender: FEMALE

Ages: 18 Years - 70 Years

Updated: 2025-09-22

1 state

Breast Cancer
Radiation
NOT YET RECRUITING

NCT07162714

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Primary Objectives: Evaluate the complete response rate (CR rate) and safety of short - course radiotherapy combined with ivonesimab (AK112) in patients with pMMR/MSS mid - low rectal cancer. Secondary Objectives: Evaluate treatment - related toxic reactions, the quality of life, long - term prognosis (local control \[LC\], disease - free survival \[DFS\] and overall survival \[OS\]). Patients will : Receive Radiotherapy: Pelvic IMRT or VMAT, DT 25Gy/5Fx. One week after radiotherapy, begin treatment with Ivorsimab (AK112) at a dose of 20mg/kg by intravenous drip on day 1. One cycle is 21 days, and a total of 6 cycles are to be carried out. Evaluate the curative effect after 3 cycles of treatment. Patients with progressive disease (PD) will withdraw from the study, and other treatment plans will be adjusted in a timely manner. Patients with CR/PR/SD will continue treatment for another 3 cycles. Conduct a comprehensive assessment after 6 cycles of treatment. Patients who achieve cCR can choose the watch - and - wait approach. For patients who do not achieve cCR, TME surgery is recommended. Decide whether to perform adjuvant chemotherapy based on the postoperative pathological findings.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2025-09-09

Rectal Cancer
Radiation
AK112
RECRUITING

NCT06253338

Optimization of Radiation Protection Through Genomic Analyses

The long-term goal is to define "signatures" in the form of genomic changes through sequence analyses of genomic DNA using modern Next Generation Sequencing (NGS) methods, which 1. determine the radiation exposure of humans. 2. provide information about the exposure (dose). 3. determine the radiation quality. 4. predict the repair capacity and radiation resistance of an individual.

Gender: All

Ages: 18 Years - Any

Updated: 2024-09-27

1 state

DNA
Cancer
Radiation
RECRUITING

NCT06214611

Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors

Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation. A particularly high benefit can be expected for patients in whom the clinical target volume (CTV) can show a significant change in shape from fraction to fraction due to anatomical deviations. The shape and position constancy of the CTV during the course of the series is examined in this trial. Dosimetric disadvantages of this type have not been reported so far. The aim of this study is to identify patients who benefit from ART at an early stage and to select them for this method, and then to continue to offer ART to this patient group. If a relevant reduction in the minimum planning target volume (PTV) margins with ART compared to IGRT is demonstrated in this study, patients could be treated with ART.

Gender: All

Ages: 18 Years - Any

Updated: 2024-09-27

1 state

Head and Neck Cancer
Adaptive Radiotherapy
Radiation
+3
RECRUITING

NCT06514118

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer

This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors, treatment resistance inevitably happens. Residual tumor irradiation my prolong drug resistance, and may help prevent the growth and spread of the tumor cells to other parts of the body.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2024-07-23

1 state

Small-cell Lung Cancer
Residual Tumor
Radiation
RECRUITING

NCT01284153

Potential Benefits of Radiotherapy in Prone Position for Breast Cancer Patients: a Planning Study

This study has the purpose to investigate the benefit of treating breast cancer patients in prone position. This treatment is compared to the standard technique in our center (supine position with or without respiratory gating). The investigators want to compare the doses on the organs at risk (heart and lungs) in the different techniques.

Gender: FEMALE

Updated: 2024-07-01

Breast Neoplasms
Radiation
RECRUITING

NCT06230549

Adaptive Radiotherapy in Patients With Gynecological Tumors

Prospective randomized evaluation of adaptive radiotherapy in the definitive radiotherapy of locally advanced gynecologic carcinoma (e.g. cervical carcinoma, endometrial carcinoma, vaginal carcinoma), in the postoperative situation or first series of external beam radiotherapy and in patients in whom radical surgery or HDR brachytherapy as dose boost is not an option.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2024-02-09

1 state

Gynecological Tumor
Adaptive Radiotherapy
Radiation
+5
RECRUITING

NCT04967976

Breast Mesh Used in Two-staged Breast Reconstruction

This is the first prospective randomized and controlled study on the efficacy and safety of TiLOOP® Bra mesh in patients with expander-implant breast reconstruction. The investigators hypothesize that incoporating TiLOOP Bra mesh with tissue expanders will reduce the rates of capsular contraction, improve the efficiency of expansion and provide better aesthetic result.

Gender: FEMALE

Ages: 18 Years - 70 Years

Updated: 2021-07-20

5 states

Breast Cancer
Radiation
Breast Reconstruction
+1
RECRUITING

NCT03920033

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy

Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a control group of standard treatment group (66 Gy, 33 fractions). The criteria for stratification at randomization include 1) risk groups, 2) androgen deprivation therapy, and 3) PSA before salvage radiation therapy, which affect biochemical recurrence. It is expected that hypofractionated, accelerated high dose radiation therapy will have a superiority in terms of biochemical control to conventional radiation therapy, and the present study would like to confirm this. In addition, we aimed to evaluate and compare the toxicity and quality of life index of two radiation therapy regimens.

Gender: MALE

Ages: 20 Years - Any

Updated: 2021-01-20

Prostate Cancer
Biochemical Recurrence
Radiation
+5